Functional Pulmonary Capillary Surface Area in BPA for CTEPH
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorJewish General Hospital
About this trial
Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.
Eligibility criteria
Qualifiers
All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
Disqualifiers
Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
Presence of patent foramen ovale
Trial design
Treatments tested in this trial
- Measurement of pulmonary functional capillary surface area
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov